Business Context and Reporting Period
Company: AnaptysBio, Inc. (Nasdaq: ANAB)
Filing Type: Form 8-K (Current Report)
Date of Report: March 7, 2022
Reporting Period: This filing announces financial results for the three months and the full year ended December 31, 2021. The specific financial data is contained in the attached press release (Exhibit 99.1) and is not detailed within the body of this 8-K text.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the press release attached as Exhibit 99.1 but are not disclosed in the filing text itself.
Material Changes
No material changes or comparative financial data are presented in the text of this filing. The document serves solely as a notification that results for the period ended December 31, 2021, have been issued.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release issued on March 7, 2022, regarding the company's financial results.
Legal Disclaimer: The information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into any registration statement unless expressly set forth by specific reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual revenue, net loss, and cash position figures for Q4 and FY 2021.
- Verify the company's cash runway and burn rate as disclosed in the attached press release.
- Check for any updates on clinical trial progress or partnership milestones mentioned in the press release.
- Confirm the status of the company's debt obligations and liquidity position as of December 31, 2021.